Pulmonary hypertension is a life-threatening medical condition, and a growing body of evidence shows that the expression of connective tissue growth factor (CTGF) is significantly associated with its pathogenesis, making it an attractive therapeutic target. Our earlier work revealed that plasmid-based CTGF-specific short hairpin RNA (shRNA) could attenuate pulmonary artery smooth muscle cell (PASMC) proliferation and pulmonary vascular remodeling in rats exposed to cigarette smoke. In this study, we explored the therapeutic role of this shRNA plasmid in the treatment of monocrotaline-induced pulmonary vascular remodeling in rats, and demonstrated that the upregulation of CTGF in PASMCs following a single injection of monocrotaline could be attenuated by administration of the shRNA. Accordingly, this shRNA was found to repress monocrotaline-induced pulmonary vascular remodeling, as evidenced by its ability to reduce the percentage of muscularized vessels and the wall thickness of pulmonary vessels. We concluded that plasmid-based shRNA against CTGF attenuated pulmonary vascular remodeling in monocrotaline-treated rats. CTGF might be a potential target for the treatment of pulmonary vascular remodeling and pulmonary hypertension.
INTRODUCTION
Pulmonary hypertension (PH) is a potentially life-threatening medical condition, and is characterized by a decrease blood circulation and elevated pressure in the pulmonary arterial circulatory system owing to progressive increased vascular resistance in lungs, resulting in vascular remodeling and right ventricular failure. 1, 2 Although the treatment of PH has been substantially improved for the past decades, the disease remains a progressive and fatal disease with unsatisfactory prognosis. The remodeling of small arteries, which could be, at least partially, attributed to the dysregulated proliferation of pulmonary artery smooth muscle cells (PASMCs), is one of the most important characteristics of PH, 3 as well as a major cause of vascular lumen narrowing. 4 However, the molecular mechanism underlying PASMCs proliferation remains largely elusive.
Firstly identified in conditioned medium from human umbilical vein endothelial cell cultures, 5 connective tissue growth factor (CTGF) is a 38 kDa, cysteine-rich protein that has been proven to be involved in the regulation of cell adhesion, migration, proliferation, extracellular matrix synthesis in a variety of cell types, such as vascular endothelial cells, fibroblasts, osteoblastic cells and smooth muscle cells. [6] [7] [8] [9] [10] [11] Considering the documented ability of CTGF to promote the proliferation of PASMCs, as well as its role in the development of pulmonary vascular remodeling, 12, 13 we hypothesized that CTGF might be a potential therapeutic target of PH and pulmonary vascular remodeling.
Our previous work showed that the upregulation of CTGF in response to cigarette smoke exposure could promote PASMCs proliferation and pulmonary vascular remodeling, 14 and a plasmid-based downregulation of CTGF successfully attenuated cigarette smoke-induced pulmonary vascular remodeling. 13 In this study, we established the animal model of pulmonary vascular remodeling by administration of a single dose of monocrotaline, with which the efficacy of short hairpin RNA (shRNA)-based anti-CTGF therapy was tested.
RESULTS

Delivery of shRNA/EXGEN500 complex in vivo
Fluorescence microscopic detection of GFP expression in lungs of experimental animals was used to evaluate the distribution of intratracheally delivered shRNA, showing that the GFP was mainly expressed in pulmonary vessels, airways and mesenchyme (Figures 1a-c) . Additionally, western blot was used to examine the transfection efficiency of the intratracheal administration of shRNA/EXGEN500 complex, and the result showed that the expression of GFP, as a marker of shRNA, was much higher in shRNA/EXGEN500 complex-treated rats than that of control ( Figure 1d ). These results indicated that the shRNA/EXGEN500 complex could be efficiently delivered to pulmonary vessels in vivo via intratracheal injection.
Monocrotaline-induced CTGF upregulation and pulmonary vascular remodeling As shown in Figures 2a and b , we found that monocrotaline treatment substantially enhanced the protein expression level of CTGF in pulmonary arteries compared with the control by using 1 western blot and immunohistochemistry (*P o 0.01). Additionally, monocrotaline treatment also significantly upregulated the protein expression level of α-smooth muscle actin (α-SM-actin) in pulmonary vessels compared with control (*P o 0.01), indicating that monocrotaline treatment could induce the proliferation of PASMC. Moreover, monocrotaline treatment directly led to increase in pulmonary vessel wall thickness and the percentage of muscularized vessels when compared with control (*P o 0.01, shown in Figures 2d and e) . Accordingly, the protein expression level of α-SM-actin in PASMCs isolated from pulmonary arteries of rats treated with monocrotaline was markedly higher than the control (Figure 2c ). These results showed that monocrotaline could induce pulmonary vascular remodeling by upregulating CTGF.
shRNA-based downregulation of CTGF expression in pulmonary vessels Our previous study has shown gene silencing effect of the plasmid-based shRNA vector in cigarette smoke-exposed rats. In the present study, we measured the effect of shRNA/EXGEN500 complex on CTGF expression in monocrotaline-treated rats. As shown in Figure 3a , the treatment with CTGF-specific shRNA significantly attenuated CTGF protein expression in rat pulmonary vessels compared with the control ( # P o 0.05 as compared), and the negative control shRNA almost had no effect on CTGF protein expression. Our data were in line with the previous reports that monocrotaline could significantly promote the expression of α-SM-actin in pulmonary vessels. Furthermore, we showed in this study that the CTGF-specific shRNA also significantly blocked monocrotaline-induced upregulation of α-SM-actin in rats ( Figure 3b , # P o0.01).
CTGF-specific shRNA attenuated pulmonary vascular remodeling Considering the facts that the upregulation of CTGF substantially contributes to the development of pulmonary vascular remodeling, and CTGF-specific shRNA significantly suppresses CTGF expression in vivo, we next evaluated its effect on pulmonary vascular remodeling induced by monocrotaline. As shown in Figure 4 , CTGF shRNA significantly lowered the percentage of muscularized vessels in monocrotaline-treated rats ( # Po0.01). In addition, Figure 5 showed that CTGF-specific shRNA also decreased the pulmonary vessel wall thickness in monocrotaline-treated rats ( # Po0.01), whereas the negative control shRNA has almost no effect on either the percentage of muscularized vessels or the wall thickness. The results demonstrated that CTGF shRNA treatment successfully inhibited the pulmonary vascular remodeling induced by monocrotaline. Nevertheless, this inhibition is incomplete. The pulmonary vessel wall thickness and the percentage of muscularized vessels in CTGF shRNA plasmid-treated rats were still higher than those in the control group.
DISCUSSION
In the present study, intratracheal administration of plasmid-based CTGF-specific shRNA was shown to be able to suppress the target gene expression in pulmonary vessels and partially ameliorate monocrotaline-induced pulmonary vascular remodeling. The data further confirmed the essential role of CTGF in the development of pulmonary vascular remodeling, and showed that pulmonary vascular remodeling induced by monocrotaline was, at least partially, mediated by the upregulation of CTGF in PASMCs.
In our previous studies, we showed that CTGF was involved in the regulation of PASMC proliferation, which is the mechanism underlying its ability to contribute to the development of PH. 13, 14 We therefore hypothesized that CTGF might be a vital therapeutic target for the treatment of PH. In this study, our results revealed that the knockdown of CTGF could successfully attenuate monocrotaline-induced pulmonary vascular remodeling, which was in line with our previous study in cigarette smoke-exposed rats. 13 Meanwhile, the knockdown of CTGF could downregulate the expression of α-SM-actin and decrease the percentage of muscularized vessels, which could be attributed to the ability of CTGF-specific shRNA to inhibit the proliferation of PASMCs in monocrotaline-treated rats. Taken together, these data confirmed that CTGF had an essential role in regulating PASMC proliferation, and significantly contributed to the development of pulmonary vascular remodeling. We also validated that CTGF was an effective therapeutic target for PH and pulmonary vascular remodeling in rats. (a-c) Lung frozen sections of shRNA/EXGEN500 complex-treated rats were stained using 4',6-diamidino-2-phenylindole (5 μg ml − 1 ) for 5 min and then observed under a fluorescence microscopy in the same visual field. (d) The smooth muscles were isolated from pulmonary vessels in shRNA/EXGEN500 complex-treated or control rats, and then prepared for western blot. CTGF has been reported to be involved in the control of a wide spectrum of biologic activities including proliferation, adhesion and migration. 15 A growing body of evidence indicated that CTGF had an important role in regulating the proliferation of smooth muscle cells, [16] [17] [18] [19] but none has depicted its role in rPASMCs. In this study, we showed that knockdown of CTGF by its specific shRNA restored the elevated CTGF expression induced by monocrotaline. These results revealed that CTGF has an important role in regulating PASMC proliferation and development of pulmonary vascular remodeling, and they were consistent with our previous study, 13 which has also explored the possible mechanism underlying the therapeutic effect of CTGF-specific shRNA in the treatment of pulmonary artery remodeling. Other than the CTGF silencing effect, we also noticed that CTGF-specific shRNA could significantly downregulate the expression of cylcin D1 and induce cell cycle arrest in PASMCs. In addition, integrin β3 pathway has also been reported to mediate the CTGF-induced proliferation of PASMCs. 20 Interestingly, the studies that were performed in other cell types represented otherwise by showing that CTGF could inhibit cell proliferation or cause apoptosis in those cells. [21] [22] [23] We reasoned that one same gene could play a distinct role in each cell type by involving in different regulatory signaling pathways.
In addition, it is noteworthy that CTGF shRNA can only partially restore monocrotaline-induced upregulation of CTGF expression and pulmonary vascular remodeling, which could be attributed to the following two reasons. First, as a non-virus vector, the shRNA/ EXGEN500 complex is unable to integrate into the genome of the host, and the infection efficiency is inferior to commonly used virus vector such as lentivirus vector or adeno-associated virus vector, which could be integrated into the genome and facilitate a stable and long-term silencing effect of the target gene. In the future, the usage of gene knockout animal model will give us a more convincing result. Second, monocrotaline might induce pulmonary vascular remodeling via modulating some pathways or regulators other than CTGF, such as sarcoplasmic reticulum Ca 2 + -ATPase 2a, caveolin-1 and phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt. [24] [25] [26] In summary, intratracheal administration of CTGF-specific shRNA downregulated the expression level of the target gene, decelerated the growth of PASMCs and ameliorated pulmonary vascular remodeling in monocrotaline-treated rats. These findings indicated that CTGF had an important role in regulating PASMCs proliferation as well as in the development of pulmonary artery remodeling, and suggested that this therapeutic approach might provide a novel treatment strategy for patients with PH.
MATERIALS AND METHODS Regents
Mouse polyclonal antibody against glyceraldehyde 3-phosphate dehydrogenase and α-SM-actin), and rabbit polyclonal antibody against CTGF were all purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Monocrotaline and 3,3′-diaminobenzidine were purchased from SigmaAldrich (St Louis, MO, USA). Trizol was bought from Invitrogen Biotechnology Co. (Carlsbad, CA, USA). Bradford assay was bought from Bio-Rad (Hercules, CA, USA). The in vivo transfection regent EXGEN500 was bought from Fermentas Biotechnology Co. (Burlington, ON, Canada).
Construction of plasmid vectors
The plasmid-based shRNA vector was constructed as described previously. 13 Briefly, the oligonucleotides for CTGF-specific shRNA or the negative control were synthesized chemically and then linked into the pGPU6/GFP vector, which contains a mouse U6 RNA polymerase III promoter. The oligonucleotide sequences for CTGF-specific shRNA or the negative control were described in previous report. 13 The sequences for the CTGF-specific shRNA were: 5′-CACCGCAATACCTTCTGCAGGCTGGA CAAGAGATCCAGCCTGCAGAAGGTATTGTTTTTTG-3′; and negative control were: 5′-CACCGTTCTCCGAACGTGTCACGTCAAGAGATTACGTGACACGTTCG Figure 3 . Specific shRNA suppressed the upregulation of CTGF in pulmonary vessels. (a) Levels of CTGF protein in explants of pulmonary vessels were evaluated using SDS-PAGE. (b) Levels of α-SM-actin protein in explants of pulmonary vessels were evaluated using SDS-PAGE. *P o0.01 as compared with control; # Po 0.01 as compared with monocrotaline. NCshRNA: negative control shRNA; CTGFshRNA: CTGF shRNA (n = 10).
GAGAATTTTTTG-3′. Direct Sanger sequencing was used to confirm the sequences of inserts before the following functional analysis.
Animal treatment and gene delivery
All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of Anhui Medical University. Forty male healthy Sprague-Dawley rats of SPF (sun protection factor) degree, weighing 200-250 g, 10 weeks old, were provided by Anhui Medical University, Experimental Animal Center and divided equally into four groups. A single injection of 60 mg kg − 1 monocrotaline was subcutaneously administered to establish the model of pulmonary vascular remodeling in rats. 27 For gene delivery in vivo, plasmid-based CTGF-specific shRNA or its negative control were mixed with EXGEN500 and 5% glucose. Rat was intratracheally treated with shRNA/EXGEN500 complex (at ratio of 100 μg/ 330 μl) every week. Instead of the plasmid vectors, normal saline was given in control rats.
Tissue preparation and morphometric analysis of pulmonary vessels After 3 weeks, all rats were killed by exsanguination and the lungs were harvested. Right lungs were fixed in 4% paraformaldehyde overnight.
Fixed tissues were embedded in paraffin and cut into 5-μm-thick sections. Explants of intrapulmonary arteries were isolated from left lungs and stored at − 80°C for future use.
Sections were deparaffinized and stained with hematoxylin and eosin. Then, the hematoxylin-and eosin-stained tissue sections were observed under a light microscope and assessment of vascular morphology was carried out as described previously. 13 The measurement was limited to small arteries (⩽50 μm in external diameter) adjacent to the alveolar ducts. In each section, at least 10 vessels were measured. As described in the previous study, the pulmonary vessel wall thickness was expressed as the percentage of the external diameter ((2 × measured wall thickness/external diameter) × 100).
Immunochemistry staining
Histologic sections were deparaffinized with xylene and ethanol. Antigen retrieval was performed using 10 mM citrate buffer, pH 6.0. The sections were blocked with 10% normal goat serum for 30 min, followed by an overnight incubation at 4°C with rabbit polyclonal antibody against CTGF (1:200). A negative control, replacing the primary antibody with goat immunoglobulin G at the same concentration, was included. Biotinylated goat anti-rabbit (diluted 1:200) was followed by an incubation with streptavidin-peroxidase conjugate. 
Assessment of pulmonary vascular remodeling
Immunohistochemical staining with anti-α-SM-actin antibody was performed for additional evaluation of pulmonary vascular remodeling. All small intrapulmonary arteries (⩽50 μm in external diameter) adjacent to the alveolar ducts were analyzed. Each vessel was categorized as nonmuscularized (actin staining o25% of the circumference), partially muscularized (actin staining 25-75% of the circumference) and fully muscularized (actin staining 475% of the circumference). The fully muscularized vessels were calculated and expressed as the percentage of total small intrapulmonary arteries. All morphometric measurements were performed by two independent researchers operating in a blinded manner. Interobserver difference in the measurements was o 5%.
Western blot analysis
Total protein was extracted from intrapulmonary arteries. Total protein concentration was determined by the Bradford method using Bradford reagent, and then separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to polyvinylidene difluoride membranes and blocked for 2 h in phosphate-buffered saline with 0.1% Tween containing 5% nonfat dried milk. The membranes were then incubated with primary antibody, CTGF (1:200), α-SM-actin (1:200) or GFP (1:500) overnight and then washed three times with phosphate-buffered saline with 0.1% Tween. The membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody (1:10 000) for 1 h, and then washed three times with phosphate-buffered saline with 0.1% Tween. Immunoreactivity was detected using an enhanced chemiluminescence Western blotting detection kit according to the manufacturer's instructions and exposed to X-ray film. Immunoblots were scanned using a GS-800 densitometer and protein bands were quantified with Quantity One software (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase was used to normalize the results before further densitometrical analysis.
Statistical analysis
All results were expressed as means ± s.e.m. Statistical analysis was carried out using one-way analysis of variance (for multiple-group comparison) followed by the least significant difference test with the computer software SPSS 12.0 (SPSS Inc., Chicago, IL, USA). For all tests, data were considered statistically significant when P o0.05.
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